Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML

ObjectivesTo compare brain MRI findings in progressive multifocal leukoencephalopathy (PML) associated to rituximab and natalizumab treatments and HIV infection.Materials and methodsIn this retrospective, multicentric study, we analyzed brain MRI exams from 72 patients diagnosed with definite PML: 32 after natalizumab treatment, 20 after rituximab treatment, and 20 HIV patients. We compared T2- or FLAIR-weighted images, diffusion-weighted images, T2*-weighted images, and contrast enhancement features, as well as lesion distribution, especially gray matter involvement.ResultsThe three PML entities affect U-fibers associated with low signal intensities on T2*-weighted sequences. Natalizumab-associated PML showed a punctuate microcystic appearance in or in the vicinity of the main PML lesions, a potential involvement of the cortex, and contrast enhancement. HIV and rituximab-associated PML showed only mild contrast enhancement, punctuate appearance, and cortical involvement. The CD4/CD8 ratio showed a trend to be higher in the natalizumab group, possibly mirroring a more efficient immune response.ConclusionImaging features of rituximab-associated PML are different from those of natalizumab-associated PML and are closer to those observed in HIV-associated PML.Key Points center dot Nowadays, PML is emerging as a complication of new effective therapies based on monoclonal antibodies.center dot Natalizumab-associated PML shows more inflammatory signs, a perivascular distribution the milky way, and more cortex involvement than rituximab- and HIV-associated PML.center dot MRI differences are probably related to higher levels of immunosuppression in HIV patients and those under rituximab therapy.

Automated summary

The study compared brain MRI findings in PML associated with rituximab, natalizumab treatments, and HIV infection. Different imaging features were observed in the three types of PML, with natalizumab-associated PML showing more inflammatory signs and cortex involvement, while rituximab and HIV-associated PML exhibited milder contrast enhancement and punctuate appearance. The differences in MRI findings may be related to varying levels of immunosuppression in the different patient groups.